Gould Capital’s Corcept Therapeutics CORT Stock Holding History

Gould Capital’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$87K	Hold	1,000	–	–	0.05%	75
2026 Q1	$40.3K	Buy	1,000 +400	+67%	+$15K	0.02%	92
2025 Q4	$20.9K	Hold	600	–	–	0.01%	120
2025 Q3	$49.9K	Buy	600 +200	+50%	+$14.5K	0.03%	86
2025 Q2	$29.4K	Hold	400	–	–	0.02%	101
2025 Q1	$45.7K	Sell	400 -200	-33%	-$12.2K	0.03%	83
2024 Q4	$30.2K	Hold	600	–	–	0.02%	100
2024 Q3	$27.8K	Hold	600	–	–	0.02%	108
2024 Q2	$19.5K	Hold	600	–	–	0.01%	125
2024 Q1	$15.1K	Buy	600 +100	+20%	+$2.36K	0.01%	131
2023 Q4	$16.2K	Hold	500	–	–	0.01%	140
2023 Q3	$13.1K	Hold	500	–	–	0.01%	136
2023 Q2	$11.1K	Hold	500	–	–	0.01%	140
2023 Q1	$10.8K	Hold	500	–	–	0.01%	143
2022 Q4	$10.2K	Hold	500	–	–	0.01%	146
2022 Q3	$13K	Hold	500	–	–	0.01%	133
2022 Q2	$12K	Hold	500	–	–	0.01%	135
2022 Q1	$11K	Hold	500	–	–	0.01%	141
2021 Q4	$10K	Buy	+500	New	+$10.1K	0.01%	158

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Gould Capital's CORT Position: Q2 2026 in Review

Gould Capital held its Corcept Therapeutics (CORT) position steady in Q2 2026 at 1,000 shares worth $87K. The position accounts for 0.05% of the portfolio, ranked #75.

Gould Capital first reported a position in CORT in Q4 2021 and has held it in 19 quarters since. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

Gould Capital held 1,000 shares of Corcept Therapeutics worth $87K as of Q2 2026.
Gould Capital left its Corcept Therapeutics share count unchanged in Q2 2026.
Corcept Therapeutics made up 0.05% of Gould Capital's portfolio in Q2 2026, its #75 holding.
Gould Capital first reported a position in Corcept Therapeutics in Q4 2021 and has held it in 19 quarters since.
423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Gould Capital's 13F filing for Q2 2026, filed 7 Aug 2026.